全脑放疗联合靶向药物治疗非小细胞肺癌脑转移临床疗效研究.docVIP

全脑放疗联合靶向药物治疗非小细胞肺癌脑转移临床疗效研究 　　摘要：目的 探究通过全脑放疗联合靶向药物治疗非小细胞肺癌脑转移的临床疗效。方法 将确诊的NCSLC脑转移患者60例平分两组，治疗组采用全脑放疗联合吉非替尼，对照组单独采用全脑放疗治疗，比较两组在颅内病灶DCR、RR，患者存活率以及不良反应的差异。结果 ①治疗组患者颅内病灶的DCR、RR均高于对照组，差异具有统计学意义（P0.05），治疗组第二年内存活率63.30%优于对照组第二年存活率43.30%比较差异明显（P0.05）。②治疗组中不良反应包括恶心呕吐及腹泻低于对照组，比较差异具有统计学意义（P0.05）。结论 WBRT联合靶向药治疗非小细胞肺癌脑转移效果优于单独使用WBRT，可进一步研究推广。 　　关键词：非小细胞肺癌；脑转移；全脑放疗；靶向药物 　　中图分类号：R734.2 文献标识码：A 文章编号：1006-1959（2017）25-0025-02 　　Abstract：Objective To investigate the clinical efficacy of whole brain radiotherapy combined with targeted drugs in the treatment of brain metastases of non-small cell lung cancer.Methods NCSLC patients with brain metastases diagnosed 60 cases divided 2 groups，treatment group were treated with whole brain radiotherapy combined with gefitinib，the control group was treated by whole brain radiotherapy treatment，the differences in the intracranial lesions DCR，RR，the difference survival rate and adverse reaction.Results ① The DCR and RR of the intracranial lesions in the treatment group were significantly higher than those in the control group（P0.05）.The survival rate in the second year of the treatment group was 63.30%，which was superior to the second-year survival rate of the control group in 43.30%，the difference was significant（P0.05）.② The adverse reactions in the treatment group included nausea，vomiting and diarrhea lower than those in the control group，with statistical significance（P0.05）.Conclusion WBRT combined with targeted drug treatment of brain metastasis of non-small cell lung cancer is better than WBRT alone，which can be further studied and promoted. 　　Key words：Non-small cell lung cancer；Brain metastases；Whole brain radiotherapy；Targeted drugs 　　肺癌是目前世界上死亡率最高的?盒灾琢黾膊。?其中以非小细胞肺癌（NSCLC）为主要类型，高达80%[1]。在NSCLC中有30%左右患者出现脑转移并发症[2]。脑转移也是晚期肺癌患者死亡的重要原因之一。目前在治疗NSCLC引起的脑转移并发症的措施中，全脑放疗（WBRT）是最具广泛认同的治疗方式，但单独采用WBRT治疗的有效率却不尽人意[3]。随着靶向药物在临床中的运用，为治疗NSCLC开辟了一条新的途径。因此，本文通过WBRT联合靶向药物探究其对NSCLC脑转移的临床疗效，现将结果报道如下。 　　1资料与方法 　　1.1一般资料 　　选取我院2011年3月～2013年3月影像检测为NSC